Silicon Valley

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Topics Earnings Economy

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

Topics Earnings Economy

January 14, 2026

This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs. ↗

February 05, 2026

Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials.

A company controlled by the Johnson family sold thousands of shares of this clinical-stage biopharmaceutical company, but that hasn't stopped the pharmaceutical stock from surging.

A 10% Owner Of Structure Therapeutics Shed Shares ↗

January 13, 2026

It's a tough act to follow.

Topics Regulatory Compliance

Can This Stock Double Again in 2026? ↗

January 11, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

Topics Artificial Intelligence Economy Intellectual Property

Why Did Structure Therapeutics Stock Surge Pre-Market Today? ↗

December 08, 2025

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

January 05, 2026

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As 2025 draws to a close, the "Magnificent Seven" era of market dominance is facing its most significant challenge yet. While the first half of the year was characterized by a relentless surge in...

Topics Artificial Intelligence ETFs Economy

The Case for Small-Cap Diversification: Why Investors are Looking Beyond Mega-Cap Tech

December 23, 2025

Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts

Topics Artificial Intelligence Economy

December 23, 2025

BAGSVAERD, Denmark — In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Novo Nordisk (NYSE:NVO) has secured U.S. Food and Drug Administration (FDA) approval for...

As 2025 draws to a close, the financial landscape has undergone a seismic shift that few predicted at the start of the year. For the first time in over half a decade, the dominant narrative of "Big...

Topics Economy

The Great Rotation: Small-Caps Seize the Spotlight as Mega-Cap Fatigue Sets In

December 22, 2025

The Great Rotation: Small-Cap Growth Surges as Investors Ditch Defensive Safety for Post-Fed Gains

Topics Economy

December 18, 2025

The financial markets are witnessing a historic "Great Rotation" this December, as the era of defensive posturing and mega-cap concentration appears to be giving way to a broad-based growth rally....

NEW YORK — In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index has finally staged its long-awaited breakout, signaling a definitive end to the years-long...

Topics Artificial Intelligence ETFs Economy

The Great Rotation: Small-Caps Break Out as Russell 2000 Hits Record Highs in Late 2025

December 18, 2025

The company's investigational GLP-1 treatment performed admirably well in a phase 2b study.

Topics Artificial Intelligence ETFs Economy

Why Structure Therapeutics Stock Doubled and Then Some on Monday ↗

December 08, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

What's going on in today's session ↗

December 08, 2025

Via Chartmill

Global Markets Brace for Fed Decision Amidst Divergent Policies and Geopolitical Crosscurrents

December 09, 2025

Global financial markets are treading a cautious path as December 9, 2025, unfolds, with investors keenly focused on the impending U.S. Federal Reserve's interest rate decision. The highly anticipated...

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Topics Artificial Intelligence Bonds Economy

Wondering what's happening in today's pre-market session? ↗

December 08, 2025

Via Chartmill

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 07, 2025

Via Benzinga

This Under-the-Radar Healthcare Stock Could Soar in 2026 ↗

September 12, 2025

We should know a lot more by year-end.

Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound ↗

August 07, 2025

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the...

Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations

August 07, 2025

Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.

Topics Economy

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors ↗

August 07, 2025

Via Benzinga

Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. ↗

August 07, 2025

An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise.

Via Investor's Business Daily

There are notable gap-ups and gap-downs in today's session. ↗

April 17, 2025

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday ↗

April 17, 2025

Via Benzinga

Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish ↗

April 15, 2025

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

Pfizer bows, but is not entirely out of the GLP-1 race.

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today ↗

April 14, 2025